These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12669469)

  • 1. Proteomics for monitoring immune responses to cancer vaccines.
    Mosca PJ; Lyerly HK; Ching CD; Hobeika AC; Clay TM; Morse MA
    Curr Opin Mol Ther; 2003 Feb; 5(1):39-43. PubMed ID: 12669469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune monitoring of T-cell responses in cancer vaccine development.
    Keilholz U; Martus P; Scheibenbogen C
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2346s-2352s. PubMed ID: 16609057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct detection of cellular immune responses to cancer vaccines.
    Mosca PJ; Hobeika AC; Clay TM; Morse MA; Lyerly HK
    Surgery; 2001 Mar; 129(3):248-54. PubMed ID: 11231452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitating therapeutically relevant T-cell responses to cancer vaccines.
    Hobeika AC; Clay TM; Mosca PJ; Lyerly HK; Morse MA
    Crit Rev Immunol; 2001; 21(1-3):287-97. PubMed ID: 11642610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
    Ayyoub M; Souleimanian NE; Godefroy E; Scotto L; Hesdorffer CS; Old LJ; Valmori D
    Clin Immunol; 2006; 118(2-3):188-94. PubMed ID: 16368270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New understanding of immunological mechanisms.
    Saalmüller A
    Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
    Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of cytokines for development of protective immunity and rational design of vaccines.
    Chabalgoity JA; Baz A; Rial A; Grille S
    Cytokine Growth Factor Rev; 2007; 18(1-2):195-207. PubMed ID: 17347024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool.
    Schultz-Thater E; Frey DM; Margelli D; Raafat N; Feder-Mengus C; Spagnoli GC; Zajac P
    J Transl Med; 2008 Oct; 6():58. PubMed ID: 18925935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring cellular immune responses to cancer immunotherapy.
    Morse MA; Clay TM; Hobeika AC; Mosca PJ; Lyerly HK
    Curr Opin Mol Ther; 2001 Feb; 3(1):45-52. PubMed ID: 11249731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods to monitor immune response and quality control.
    Whiteside TL
    Dev Biol (Basel); 2004; 116():219-28; discussion 229-36. PubMed ID: 15603195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting T cell responses to biological warfare vaccines in human vaccinees.
    Allen JS; Skowera A; Rubin GJ; Wessely S; Peakman M
    Clin Infect Dis; 2006 Jul; 43(1):1-7. PubMed ID: 16758411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.